Skip to main content

Table 2 HR (95% CI) for risk of myocardial infarction according to quartiles of the TyG index

From: Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort

Variables Quartiles of the TyG index Per 1 unit increase P for trend
Q1 Q2 Q3 Q4
Baseline TyG index
Case, n (%) 220 (0.89) 315 (1.27) 430 (1.74) 590 (2.39)   
Incidence rate, per 1000 person-y 0.84 (0.74–0.96) 1.21 (1.08–1.35) 1.65 (1.51–1.82) 2.28 (2.11–2.48)   
Model 1 Reference 1.39 (1.17–1.65) 1.88 (1.60–2.21) 2.69 (2.30–3.14) 1.61 (1.51–1.72)  < 0.0001
Model 2 Reference 1.33 (1.12–1.58) 1.73 (1.47–2.05) 2.41 (2.06–2.83) 1.54 (1.43–1.65)  < 0.0001
Model 3 Reference 1.26 (1.06–1.50) 1.60 (1.36–1.89) 2.08 (1.77–2.45) 1.43 (1.33–1.53)  < 0.0001
Sensitivity analysisa Reference 1.24 (1.01–1.51) 1.62 (1.34–1.96) 2.02 (1.67–2.44) 1.39 (1.28–1.52)  < 0.0001
Sensitivity analysisb Reference 1.22 (1.02–1.46) 1.50 (1.24–1.82) 3.60 (1.48–8.80) 1.63 (1.32–2.02)  < 0.0001
Updated mean TyG index
Case, n (%) 264 (1.07) 318 (1.29) 421 (1.70) 552 (2.23)   
Incidence rate, per 1000 person-y 1.02 (0.90–1.15) 1.22 (1.09–1.36) 1.61 (1.46–1.36) 2.13 (1.96–2.32)   
Model 1 Reference 1.20 (1.00–1.43) 1.54 (1.24–1.94) 2.10 (1.57–2.79) 1.74 (1.48–2.04)  < 0.0001
Model 2 Reference 1.13 (0.95–1.36) 1.42 (1.14–1.78) 1.86 (1.39–2.49) 1.64 (1.39–1.93)  < 0.0001
Model 3 Reference 1.07 (0.90–1.29) 1.30 (1.03–1.62) 1.58 (1.18–2.12) 1.49 (1.26–1.76)  < 0.0001
Sensitivity analysisa Reference 1.01 (0.78–1.20) 1.24(1.02–1.58) 1.42 (1.13–2.05) 1.47 (1.32–1.63)  < 0.0001
Sensitivity analysisb Reference 1.17 (0.86–1.59) 1.21 (0.90–1.64) 1.80 (1.36–2.38) 1.86 (1.25–2.57)  < 0.0001
  1. CI confidence interval, HR hazard ratio, TyG triglyceride glucose
  2. Model 1, adjusted for age and sex at baseline
  3. Model 2, adjusted for variables in model 1 plus level of education, income, smoking, alcohol abuse, physical activity, and BMI at baseline
  4. Model 3, adjusted for variables in model 2 plus SBP, DBP, a history of hypertension, diabetes mellitus, and dyslipidemia, antidiabetic drugs, lipid-lowering drugs, antihypertensive drugs, HDL-C, LDL-C, and hs-CRP at baseline
  5. aSensitivity analysis was adjusted for variables in model 3 and further excluded all deaths during the follow-up visits
  6. bSensitivity analysis was excluded those with abnormal FBG (≥ 7.0 mmol/L) or abnormal TG level (≥ 1.7 mmol/L) at baseline, and adjusted for covariates in Model 3